Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12072489 | 0.90 | RAB9A (0.39) | LMNAP2RX7CCNE2CCNE1CDK2 | |
| SCHEMBL14477481 | 0.83 | RAB9A (0.46) | P2RX7CCNE2CCNE1CDK2 | |
| SCHEMBL12324923 | 0.80 | HSP90AB1 (0.47) | LMNAHDAC1 | |
| SCHEMBL18331391 | 0.73 | CDK2 (0.48) | CCNE2CCNE1CDK2 | |
| SCHEMBL12072535 | 0.73 | MTOR (0.53) | MTORHDAC1HDAC2 | |
| SCHEMBL22412661 | 0.73 | P2RX7 (0.55) | LMNAP2RX7CCNE2CCNE1CDK2 | |
| SCHEMBL12072486 | 0.72 | CCNE2 (0.38) | LMNAP2RX7CCNE2CCNE1CDK2 | |
| SCHEMBL15499105 | 0.72 | HDAC6 (0.39) | HDAC1 | |
| SCHEMBL7852502 | 0.71 | CDK5 (0.36) | P2RX7CCNE2CCNE1CDK2 | |
| SCHEMBL20836970 | 0.70 | ACHE (0.40) | LMNACCNE2CCNE1CDK2MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653269-B2 | Process for preparation of t-butoxycarbonylamine compounds | NIPPON SODA CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20130005981-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | NIPPON SODA CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| WO-2011111705-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | 日本曹達株式会社 (JP) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005981-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | BPGM, TST, BET1 | LMNA 2253/4885P2RX7 4708/4885CCNE2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.